Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
An Open Letter to Highmark and Independence Blue Cross
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
FDA Converts Lecanemab to Traditional Approval
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
Dr. Klein Receives American Headache Society Distinguished Service Award
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
FDA Gives Accelerated Approval to New ALS Treatment
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
Dr. Weisman participates in FDA Advisory Committee
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
ANA administers first lecanemab infusion in PA
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Lecanemab Reduces Cognitive Decline in Alzheimer’s
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
